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Sequential multicomponent synthesis of 2-(imidazo[1,5-α]pyridin-
1-yl)-1,3,4-oxadiazoles  
 
Santosh Kurhade,[a]†Markella Konstantinidou,[a]†Fandi Sutanto,[a]Katarzyna Kurpiewska,[b]Justyna 
Kalinowska –Tłuścik,[b]and Alexander Dömling*[a] 
Dedication ((optional)) 
Abstract: A 21 membered library of 2-(imidazo[1,5-α]pyridine-1-yl)-
1,3,4-oxadiazoles is synthesized in an unprecedented short 
sequence starting from an Ugi-tetrazole reaction with a cleavable 
isocyanide component. The intermediate tetrazole is subjected to an 
acetic anhydride-mediated cyclization, followed by a Huisgen-type 
rearrangement with acyl chlorides to afford the imidazopyridine-
oxadiazole bis-heterocycles. The scope and limitations of the 
methodology were investigated with substitutions on both the 
oxadiazole and the imidazopyridine rings. The herein introduced 
enabling technology for imidazopyridine oxadiazole synthesis 
combines a short reaction sequence with high scaffold diversity, 
based on commercially available starting materials and high 
functional groups tolerance.   
Undoubtfully, heterocycles are the cycles mostly used in drug 
discovery. New, elegant synthetic routes towards heterocycles 
are still of high demand in order to shorten reaction schemes, 
simplify synthetic routes and in some cases discover greener 
approaches with high atom economy. Most of the above 
attributes are fulfilled by multi-component reaction chemistry 
(MCRs), which in contrast to traditional step-wise synthesis, 
allows the synthesis of complex structures in a few synthetic 
steps, starting from commercially available or easily accessible 
starting materials.[1] For instance, multi-component reaction 
chemistry has been used extensively for the diverse synthesis of 
tetrazole derivatives,[2]  leading to complex scaffolds that cannot 
be accessed via the nitrile precursors. In this communication, we 
show a short, sequential reaction scheme that leads via multi-
component reaction chemistry with a cleavable isocyanide and a 
subsequent Huisgen rearrangement to the general synthesis of 
2-(imidazo[1,5-α]pyridine-1-yl)-1,3,4-oxadiazoles (Scheme 1). 
The bis-heterocycle scaffold was recently described in a series 
of 5-HT4 receptor partial agonists with applications in 
Alzheimer’ s disease.[3] The original imidazo[1,5-α] pyridine 
scaffold was further developed by changing its amide substituent 
to its stable bioisostere, 1,3,4-oxadiazole. The series were 
further improved,[4] however the synthesis schemes remain quite 
lengthy and this could be a deterrent factor for the development 
of the scaffold in the future. Compounds with the same bis-
heterocycles were also described as topoisomerase IIα inhibitors 
(Scheme 1).[5] It should be noted that in both cases the two 
heterocycles are constructed separately in a multi-step synthesis. 
Scheme 1.   
 
Moreover, 1,3,4-oxadiazole derivatives have been extensively 
studied due to a broad spectrum of biological activities, including 
mainly antiviral,[6] anti-inflammatory,[7] analgetic,[7] antimicrobial,[8] 
anti-convulsant,[8] anti-depressant,[8] antipsychotic and 
anticancer.[8] In medicinal chemistry, they are well-established 
bioisosteres for esters, amides, carbamates and hydroxamic 
esters and they act, quite often, as hydrogen bond acceptors in 
ligand–receptor interactions.[9] Moreover, 1,3,4-oxadiazoles find 
applications as charge carrier transporting molecular materials[10] 
and as fluorescent sensors,[11] due to their spectral luminescent 
properties.[12] Regarding the synthetic routes for 1,3,4-
oxadiazoles the most common procedures include the oxidative 
cyclization of N-acylhydrazones, the cyclodesulfurization of N-
acyl-thiosemicarbazides, the cyclodehydration of aldehydes and 
hydrazides, and the reaction of carboxylic acids and acyl 
hydrazines with a great variety of reagents and conditions.[13]  
Recently, a mild synthetic route was described for 1,3,4-
oxadiazoles using (isocyanoimino)triphenylphosphorane.[14a-d] 
More specifically, a two-component reaction synthesis of 2-aryl-
1,3,4-oxadiazoles is described using the above mentioned 
reagent and benzoic carboxylic acids under ultrasound 
irradiation.[14a] Variations of this procedure include a three-
component reaction with the same reagent, a carboxylic acid 
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and acenaphthoquinone under ultrasound irradiation[14b] or four-
component reactions with (isocyanoimino)triphenylphosphorane, 
chloroacetone, a primary amine and a carboxylic acid[14c] or a 
benzylamine, pyrrole-2-carbaldehyde and a carboxylic acid at 
room temperature.[14d] In all those cases, the transformation 
occurs through an aza-Wittig reaction leading to the desired 
1,3,4-oxadiazole scaffold, with triphenylphosphine oxide as side-
product. Moreover, a one-pot synthesis of α-keto-1,3,4-
oxadiazoles was described using an isocyanide-Nef reaction 
through a sequential intermolecular dehydrochlorination / 
intramolecular aza-Wittig reaction.[15]  
Of note, the transformation of tetrazoles to 1,3,4-oxadiazoles, 
also called Huisgen reaction, is significantly less common. The 
Huisgen reaction is performed with tetrazoles and acyl chlorides, 
usually in refluxing pyridine[ [16] or o-xylene.[17] A few examples 
are reported for microwave-assisted synthesis either from acyl 
chlorides or anhydrides. [18] In all those cases, the tetrazoles are 
formed from nitrile precursors.  To the best of our knowledge, 
tetrazoles deriving from the Ugi-tetrazole reaction are not 
explored in the concept of Huisgen reaction.   
Herein, we present the synthesis of 2-(imidazo[1,5-α]pyridine-1-
yl)-1,3,4-oxadiazoles starting from an Ugi-tetrazole reaction with 
a cleavable isocyanide. Example 7a (Table 1, entry 1) was 
selected for establishing the methodology. Equimolar amount of 
picolinaldehyde (1), tritylamine (2), tert-octyl-isocyanide (3) and 
trimethylsilylazide (4) were combined sequentially in methanol 
(0.5M) at 50 oC. The corresponding Ugi-tetrazole product (5) 
was isolated after 48 h by a quick filtration with diethylether and 
was directly subjected to acid mediated trityl group deprotection. 
The obtained amine HCl salt (6) was treated with acetic 
anhydride (0.5 M) and 4 N HCl/dioxane (3.0 equiv). [19] The 
reaction mixture was heated at 120 oC for 2 h in a heating metal 
block and after column chromatography afforded the 
corresponding 1,3,4-oxadiazole in 60% yield. The one pot–one 
step example intermediate 6 was subjected in-situ to an acetic 
anhydride – mediated N-acylation-cyclization, tert-octyl group 
deprotection and rearrangement of the tetrazole towards an 
oxadiazole (Scheme 2). 
 
Scheme 2. Establishing the methodology and the one pot – one step 
procedure. 
Next, we were keen to investigate the R1 substitutions on the 
imidazo[1,5-α]pyridine ring by using a one pot–two step 
procedure. For this aim, the amine HCl intermediate (6) was 
treated with acyl chlorides, triethylamine and DCM at room 
temperature for 24 h to afford the amide intermediates A. The 
solvents were removed and intermediates A were directly 
treated with acetic anhydride (0.5 M) and 4 N HCl/dioxane (1.0 
equiv). The reaction mixtures were heated at 120 oC for 2 h in a 
heating metal block to afford the cyclized R1 – substituted 
oxadiazoles (7b- 7j).  
 























































     
[a] Reaction scale was 1mmol.  [b] Isolated yield after column 
chromatography. [c] Product was obtained using acetic anhydride.  
 
 
For the R1-substitution, both aromatic and aliphatic acyl 
chlorides were tolerated. Functional groups, including esters and 
thioethers reacted smoothly. Lower yields were observed with 
pivaloyl chloride (16%, 7j) and isobuturyl chloride (17%, 7h), 
whereas cyclopropanecarbonyl chloride gave a better yield (42%,  
7i) and 2-cyclohexylacetyl chloride led to an excellent yield (92%, 
7c). High yields were obtained in the cases where a methylene 
group was between the imidazopyridine ring and either an 
aromatic (85%, 7b) or aliphatic ring (92%, 7c). However, in the 
absence of the methylene, both for linear (17%, 7h; 16%, 7j) 
and cyclic acyl chlorides (42%, 7i) or aromatic acyl chlorides (7g, 
32%) the observed yields were lower. One plausible explanation 
for the variation of those yields is steric hindrance, either in the 
initial N-acylation step or in the ring closure of the 
imidazopyridine ring.  
 
For the product 7b an X-ray single crystal structure was 
obtained, confirming the structure. In the solid state, the rings of 
1,3,4-oxadiazole and imidazo[1,5-α]pyridine are flat and 
coplanar. The o-fluorophenyl rings of two molecules are showing 
T-shaped pi stacking. 
Figure 1. X-ray structure of compound 7b.  
 
Moreover, we investigated to increase diversity by changing 
the methyl substituent of the oxadiazole ring to more general R2- 
substituted 1,3,4-oxadiazoles. The obtained amine HCl salt (6) 
was treated with acetic anhydride [0.5M] at 75 oC for 1h, 
following our previously reported methodology.[19] No base was 
required, only acetic anhydride and heating. The imidazopyridine 
intermediate B was treated with 4N HCl / dioxane to deprotect 
the tert-octyl group and to give 3-methyl-1-(1H-tetrazol-5-
yl)imidazo[1,5-α]pyridine (compound 8a). This intermediate 
tetrazole 8a was directly dissolved in pyridine (0.5M) and was 
reacted with 4-chlorobenzoyl chloride. The reaction mixture was 
heated at 120 oC overnight and after column chromatography 
the product 9 was isolated with 80% yield.  
 
 
Scheme 3. Establishing the methodology for substitution on the oxadiazole 
ring. 
Next, we investigated the scope of R2-substitutions and at the 
same time changed the methyl substituent of the imidazo-
pyridine system towards an isobuturyl group to further diversify 
the products (Scheme 4). The isobuturyl substituent was a key 
feature in a series of 2-imidazo[1,5-a]pyridine-1,3,4-oxadiazole 
derivatives described as 5-HT4 receptor partial agonists.[3] 
 
Scheme 4. Synthetic route for products 10a-j.  




























































[a] Reaction scale was 0.5 mmol.  [b] Isolated yield after column 
chromatography.  
Overall, both aliphatic and aromatic acid chlorides were well 
tolerated. Excellent yields were observed with halogen-
substituted aromatic acyl chlorides (products 9, 10a and 10j), 
whereas the presence of electron-donating methoxy groups 
(10i) significantly reduced the yield. Aliphatic acyl chlorides, 
such as 2-cyclohexylacetyl chloride (10b), isobutyryl chloride 
(10e) and 3-(methylthio)propanoyl chloride (10d) led to very 
good yields. On the other hand, the cyclopropanecarbonyl 
chloride (10g) and 2-(2-fluorophenyl)acetyl chloride (10h) 
reacted with a low yield. Regarding acyl chlorides with ester 
groups, methyl 5-chloro-5-oxopentanoate (10c) gave the 
expected product with 40% yield, whereas ethyl 2-chloro-2-
oxoacetate unexpectedly resulted in the cleavage of the ester 
group towards the mono-substituted oxadiazole (10f) with a yield 
of 64%. This type of oxadiazoles are usually formed from the 
reaction of the corresponding hydrazide and triethylorthoformate 
and are useful intermediates for arylation reactions with boronic 
acids, [20] iodination [21] and C-H bond thiolation. [22] Only one acyl 
chloride failed to react in these conditions, the tert-butyl 1-
(chlorocarbonyl)piperidine-4-carboxylate, which was prepared in 
situ from the corresponding carboxylic acid with thionyl chloride. 
In this case, unreacted intermediate 8b was recovered.  
A possible mechanism is proposed in Scheme 5.The trityl group 
of the Ugi-tetrazole product (5) is cleaved under acidic 
conditions. The intermediate amine salt (6) is N-acylated by the 
acyl chloride and further undergoes an O–acylation by the acetic 
anhydride (intermediates A-i, A-ii), followed by an elimination 
of acetic acid that leads to a nitrilium intermediate (intermediate 
A-iii). The latter, after an attack of the pyridine nitrogen’s 
electron lone pair on the triple bond, affords the cyclic 
intermediate (intermediate A-iv) that aromatizes (intermediate 
B-i). The deprotection of the tert-octyl group under acidic 
conditions gives the mono-substituted tetrazole (intermediate 
B), which is N-acylated by the corresponding acyl chloride 
(intermediate 8-i). The unstable N-acylated tetrazole, 
undergoes the Huisgen rearrangement with nitrogen elimination, 
ring opening (intermediate 8-ii) and final cyclization towards the 
2-(imidazo[1,5-α]pyridine-1-yl)-1,3,4-oxadiazole (10).In particular, 
for the formation of compound 10f, the N-acylation of 
intermediate 8 by ethyl 2-chloro-2-oxoacetate leads to an 
unstable intermediate, where the elimination of nitrogen and ring 
opening are making the adjacent ethyl ester a good leaving 
group, which is eliminated as ethanol and carbon dioxide, thus 
affording the mono-substituted product 10f.  
 
Scheme 5. Proposed reaction mechanism. 
 
Overall, we have developed an efficient synthetic procedure for 
the synthesis of the 2-(imidazo[1,5-α]pyridine-1-yl)-1,3,4-
oxadiazoles based on the Ugi–tetrazole reaction and the 
Huisgen rearrangement. The current methodology allowed the 
diverse library synthesis from simple building blocks in a short 
fashion and with great functional group compatibility. The final 
products show applicability in medicinal chemistry, materials 
chemistry and fluorescent probes.   
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